Core Viewpoint - A class action lawsuit has been filed against Aldeyra Therapeutics on behalf of investors who acquired its securities during the specified class period from November 3, 2023, to March 16, 2026 [1] Summary by Relevant Sections - **Company Information** - Aldeyra Therapeutics is identified as a publicly traded company on NASDAQ under the ticker symbol ALDX [1] - **Legal Proceedings** - The lawsuit is initiated by the law firm Kirby McInerney LLP, targeting investors who suffered losses on their Aldeyra investments during the class period [1] - Investors have until May 29, 2026, to request lead plaintiff appointment, indicating a timeline for potential claimants [1]

Core Viewpoint - A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for securities fraud, with the Rosen Law Firm representing investors who purchased securities between November 3, 2023, and March 16, 2026 [1]. Group 1: Lawsuit Details - The lawsuit alleges that during the Class Period, Aldeyra made false and misleading statements regarding the clinical trials of its drug candidate reproxalap, leading to unreliable positive findings [5]. - Investors who purchased Aldeyra securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Investors wishing to join the class action must move the Court by May 29, 2026, to serve as lead plaintiff, representing other class members in the litigation [3]. - The Rosen Law Firm encourages investors to select qualified counsel with a successful track record in securities class actions [4].

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $5.6 million, down from $7.7 million in 2024, primarily due to the timing of customer equipment purchases [13] - Gross margin improved to approximately 55%, up from 46% in 2024, reflecting lower cost of sales and a reduction in inventory reserves [13] - Total operating expenses decreased by approximately 10% to $6.9 million from 2024 [14] - The net loss improved to $3.7 million or $0.19 per share, compared to a net loss of $4.5 million or $0.22 per share in 2024 [14] Business Line Data and Key Metrics Changes - The backlog of orders for support services increased by 16%, and BIT Solution orders rose by 24% in Q1 2026 compared to the same period last year, indicating a growing recurring revenue trajectory [10][16] - The SteraMist Integrated System achieved its first commercial installation at a leading CDMO in June 2025, with four fully operational installations by year-end [4] - A signed purchase contract of $500,000 was secured in December 2025 for integration into sterile manufacturing [5] Market Data and Key Metrics Changes - The FDA's late 2025 approval of hydrogen peroxide as a direct food additive is a significant regulatory moment, leading to engagements with major partners like Danone and Nestlé [8] - The global ethylene oxide market was valued at $5.29 billion last year, with rising demand for sterilized medical consumables driving growth [11] Company Strategy and Development Direction - The company is focusing on execution and converting its pipeline into recognized revenue while advancing its technology platform [12] - A shift towards a recurring revenue model is emphasized, moving from episodic revenue to embedded revenue, which is expected to enhance customer dependency on the company's solutions [32][33] - The company is prioritizing open bid solution orders and annual service offerings to drive additional revenue and deeper product adoption [16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2025 was a challenging year but expressed optimism about the future, highlighting operational momentum and a growing customer base [4][11] - The management noted that customers are beginning to move forward with deferred capital expenditure projects, indicating signs of improvement in the economic environment [58] Other Important Information - The company received approvals from the HSE and BPR submissions, enhancing its recognition in the UK and the Netherlands [10] - The company is preparing to introduce its IHP device to the U.S. market through the FDA 510(k) pre-market notification process [11] Q&A Session Summary Question: Insights into global opportunities mentioned in the quarter - Management expects many EU states to follow suit with registrations, leveraging existing relationships and distributors [41] Question: Thoughts on operating expenses going forward - Operating expenses are expected to slightly decrease as a percentage of revenue growth, with leverage already in place [43] Question: Signs of improvement in customer CapEx projects - Management confirmed that they are seeing customers who deferred projects beginning to move forward [58] Question: Details on BIT Solution revenues for 2025 versus 2024 - There was an increase in BIT Solution usage, with customers moving towards auto shipment and advanced orders [62] Question: Potential military applications for SteraMist - Management acknowledged the idea and indicated they would explore opportunities with the military, particularly in light of recent health concerns [75]

As filed with the Securities and Exchange Commission on March 31, 2026 Registration No. 333-292829 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S‑3 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LeonaBio, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2836 45-3368487 (I.R.S. Employer ...

Core Insights - HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing fusion immunotherapeutics for chronic inflammation-related diseases, including autoimmune disorders and cancer [1][18] - The company reported financial results for the three months ended December 31, 2025, highlighting a significant decrease in revenues and a net gain for the quarter [11][15] Clinical Development - The company initiated its first-in-human clinical trial for HCW9302, targeting alopecia areata, with a focus on evaluating safety and determining recommended dose levels [2][4] - HCW9302 is designed to activate and expand regulatory T cells to suppress auto-reactive immune cells, addressing a condition that affects approximately 160 million people globally [3][4] - Preliminary human data readout from the Phase 1 study is expected in the first half of 2026 [4] Business Highlights - HCW Biologics received a $3.5 million upfront licensing fee for HCW11-006, licensed to Beijing Trimmune Biotech Co., Ltd., with potential for additional milestone payments and royalties [6][7] - The company launched two proprietary fusion protein molecules as commercial-ready reagents to support cell-based immunotherapeutics, aiming to generate revenue to offset development costs [9] Financial Performance - Revenues for Q4 2025 were $27,010, a significant drop from $394,804 in Q4 2024, with total revenues for the year decreasing from $2.6 million to $54,232 [11] - Research and development expenses increased by 27% in Q4 2025 compared to Q4 2024, while total R&D expenses for the year decreased by 15% [12] - General and administrative expenses decreased by 26% in Q4 2025, but increased by 13% for the full year [13] - The company reported a net gain of $2.2 million for Q4 2025, compared to a net loss of $3.4 million in Q4 2024, and a reduced net loss for the year from $30 million to $6.5 million [15] Financial Guidance - As of December 31, 2025, the company expressed substantial doubt regarding its ability to continue as a going concern without additional funding [16] - The company regained compliance with Nasdaq listing rules but faces ongoing monitoring and potential delisting risks due to stock price fluctuations [17]

Core Viewpoint - ZyVersa Therapeutics, Inc. is positioned for transformative growth over the next 18 months, focusing on developing first-in-class drugs for inflammatory and renal diseases with significant unmet medical needs [1]. Financial Results - As of December 31, 2025, the company reported cash on hand of $0.1 million and raised $1 million through convertible promissory notes and warrants in February 2026 [3][5]. - Research and development expenses for the year ended December 31, 2025, were approximately $1.1 million, a decrease of 37.4% from 2024, attributed to reduced consultant usage and program pauses [4]. - General and administrative expenses were approximately $5.7 million for the year ended December 31, 2025, a decrease of 22.1% from 2024, due to lower insurance costs and reduced marketing expenses [6]. - The net loss for the year ended December 31, 2025, was approximately $25.0 million, a significant increase from a net loss of $9.4 million in 2024, primarily due to an impairment of in-process research and development [7][15]. Pipeline and Development Plans - ZyVersa is advancing a differentiated pipeline targeting inflammatory and renal diseases, with a total accessible market exceeding $100 billion [5]. - The company is nearing completion of its preclinical program for Inflammasome ASC Inhibitor IC 100, with plans to file an IND in Q4-2026 and initiate a Phase 1 trial in Q1-2027 [2]. - A Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with FSGS and Alport Syndrome is set to begin in Q2-2026, with an interim read-out expected around Q4-2026 [2][5]. Funding and Financial Outlook - The company anticipates needing additional financing to support ongoing operations and meet clinical milestones, exploring options such as public or private equity, debt financing, and collaborations [8].

TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 FORM S‑3 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 LeonaBio, Inc. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on March 31, 2026 Registration No. 333-292826 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2836 45-3368487 (I.R.S. Employer ...

Core Insights - Cognition Therapeutics is making significant advancements in developing treatments for neurodegenerative diseases, particularly focusing on zervimesine (CT1812) for dementia with Lewy bodies (DLB) and Alzheimer's disease [2][4][5] Company Progress - The company has reported strong results from the Phase 2 SHIMMER trial for zervimesine in DLB, showing favorable impacts across various symptom domains, particularly in neuropsychiatric inventory assessments [3][5] - The Phase 2 START study, which includes 545 participants with mild cognitive impairment (MCI) and early Alzheimer's disease, is fully enrolled and expected to provide data readouts in the second half of 2027 [7] Clinical Trials and Regulatory Engagement - The FDA has aligned with the company's Phase 3 program design for zervimesine, focusing on participants with low levels of p-tau217, which is associated with a significant reduction in cognitive decline [6][5] - The company plans to meet with the FDA's Division of Psychiatry in Q2 2026 to discuss the registrational plan for zervimesine in treating DLB psychosis [4] Financial and Funding Aspects - The START trial is fully funded by an NIH grant, ensuring that costs are covered through the study's completion in 2027 [7] - Cognition Therapeutics has received nearly $200 million in grants from the National Institutes of Health and related foundations to support its research efforts [9] Future Outlook - The company expresses confidence that the achievements of 2025 will propel zervimesine closer to providing effective treatment options for patients in 2026 [8]

Core Insights - Edesa Biotech's CEO, Dr. Par Nijhawan, has been selected to present at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the Phase 3 results for paridiprubart in treating ARDS patients [1][3] Group 1: Presentation and Study Results - Dr. Nijhawan's presentation will focus on findings from the Phase 3 study of paridiprubart (EB05), an anti-TLR4 antibody for Acute Respiratory Distress Syndrome (ARDS), which leads to over three million ICU admissions globally each year [2] - The Phase 3 results include data from an initial 104 patients requiring invasive mechanical ventilation and expanded results from a broader 278-patient population, reinforcing the potential clinical benefits of paridiprubart [2] Group 2: Upcoming Events - The presentation by Dr. Nijhawan is scheduled for May 15, 2026, with an accompanying poster presentation by Edesa's research team at the summit [3] - Ted Steiner, MD, will present a full oral presentation of the Phase 3 results on May 20, 2026, during the ATS 2026 International Conference, focusing on the study's design and outcomes [4] Group 3: Product Overview - Paridiprubart is a new class of host-directed therapeutics designed to modulate the immune response against various health threats, including infectious diseases and other public health emergencies [5] - The drug works by inhibiting toll-like receptor 4 (TLR4), which is activated by various pathogens and is involved in chronic autoimmune diseases [5] Group 4: Company Background - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory and immune-related diseases, with a pipeline that includes therapies for both medical dermatology and respiratory conditions [6] - The company is developing EB06 for vitiligo and EB01 for allergic contact dermatitis, alongside its lead respiratory candidate, paridiprubart, which is supported by funding from the Government of Canada [6]

Core Insights - Edesa Biotech, Inc. has announced that its CEO, Dr. Par Nijhawan, will deliver the inaugural presentation at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the company's Phase 3 study results for paridiprubart, an anti-TLR4 antibody for treating Acute Respiratory Distress Syndrome (ARDS) [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, with a clinical pipeline targeting Medical Dermatology and Respiratory conditions [6] - The company is developing paridiprubart (EB05) as a treatment for ARDS, a condition that leads to over three million ICU admissions globally each year [2][6] Clinical Study Details - The Phase 3 study of paridiprubart has reported results from an initial cohort of 104 patients requiring invasive mechanical ventilation, followed by expanded results from a total of 278 patients, indicating potential clinical benefits [2] - Dr. Ted Steiner, the principal investigator of the Phase 3 study, will present comprehensive results at the ATS 2026 International Conference on May 20, 2026 [4] Presentation Significance - Dr. Nijhawan expressed that being invited to lead the innovation showcase is a validation of the strength of the Phase 3 data and the potential of paridiprubart to transform ARDS treatment, which currently has limited effective options [3] Therapeutic Mechanism - Paridiprubart represents a new class of host-directed therapeutics designed to modulate the immune response against various public health threats, including infectious diseases and other emergencies [5]